retatrutide phase 2 trial obesity nejm 2023 triple agonist Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Want to learn more about

If gut bacteria do not break down oxalates, they are typically excreted in the stool out of the gut

Tirzepatide activates the GLP-1 receptor just as semaglutide and liraglutide do, but it also activates glucose-dependent insulinotropic polypeptide (GIP)

So, let's revise 3 healthy eating essentials

Substances like CoQ10, methylated B vitamins, and N-Acetylcysteine act as antioxidants, supporting cellular health and reducing neuroinflammation

For a patient with untreated Cushings disease or on high-dose glucocorticoid therapy, an elevated serum IGF-I may be observed, but levels decrease following remission or cessation of glucocorticoid therapy, respectively